{"slug":"randomised-phase-2","tag":"randomised-phase-2","variants":["randomised-phase-2"],"description":"No description yet","count":1,"kinds":{"paper":1},"related":[{"slug":"education-audit","tag":"education-audit","shared":1}],"records":[{"id":"paper-future-super-lancet-oncology-2024","kind":"paper","name":"FUTURE-SUPER: first-line subtyping-based treatment in advanced TNBC","route":"/key-papers/paper-future-super-lancet-oncology-2024/","tldr":"This randomised phase 2 trial found longer progression-free survival with a specified subtype-based combination strategy than with nab-paclitaxel alone, with more serious treatment-related adverse events."}]}